



# Incidenza delle complicanze cardiovascolari – lo studio DAI

Carlo Giorda

M. Metaboliche e Diabetologia ASL8 Regione Piemonte  
Comitato scientifico Studio DAI

# Diabete Tipo 2

## Complicanze Tardive


---

- ◆ **Le complicanze tardive sono una causa importante di incremento di morbidità e mortalità**
- ◆ **Il 25% ha già complicanze in atto al momento della diagnosi<sup>1</sup>**
- ◆ **L'incidenza di Cardiopatia Ischemica è da 2 a 4 volte superiore a quella dei non diabetici<sup>2</sup>**
- ◆ **La malattia cardiovascolare è la causa maggiore di morbidità e mortalità**

<sup>1</sup>UKPDS: Diabetologia 34, 877, 1991; <sup>2</sup>Haffner et al.: Am J Med 103, 152, 1997


# Diabete tipo 2

Prevalenza delle complicanze alla diagnosi



Dagogo-Jack et al.: Arch. Int. Med. 157, 1802, 1997

# Natural history of type 2 diabetes



# IL CONTENITORE DIABETE TIPO 2




# Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

DCC/EDIC Research Group

*N Engl J Med, 2005*

# Cardiovascular Events

## *Non-Fatal MI, Stroke or CVD Death*



### *Number at Risk*

Intensive	705	686	640	118
Conventional	721	694	637	96

# Intensive Therapy and Cardiovascular Disease

- The 57% reduction in non-fatal myocardial infarctions and strokes and cardiovascular death in Type 1 diabetes exceeds risk reduction with aggressive management of hypertension and hypercholesterolemia in other populations



# RR e cause di mortalità nel T2DM negli studi Whitehall, Paris Prospective, Helsinki Policemen

Cause	Whitehall	Paris Prosp	Helsinki Pol
Tutte	2,48	2,16	2,06
Malattie CV	2,56	2,17	2,75
CHD	3,19	2,12	3,52
CerebroVascol	-	2,39	1,54
Neoplasie	1,47	1,76	0,53
Altre cause	4,27	2,81	2,18

Follow-up 20 anni Balkau B et al: Lancet 350, 1680, 1997

## RR di mortalità nei diabetici in rapporto ai paesi di origine

Paese	Studio	Mortalità (RR)	
		Da ogni causa	Coronarica
USA	PHS*	2,3	3,3
Finlandia	Helsinki	2,06	3,52
UK	Whitehall	2,48	3,19
Francia	Paris	2,16	2,12
Europa	DECODE	1,81	1,94
Italia	Verona	1,42	1,41

# Variazioni nella mortalità tra il 1971-75\* e il 1982-84^ nei due sessi in diabetici e non

Cause	Diabetici		Nondiabetici	
	Maschi	Femmine	Maschi	Femmine
Tutte	- 1,1	+ 10,7	- 19,7	- 12,9
Cardiopatie	- 10,0	+ 22,9	- 32,0	- 27,1
Card. Ischemica	- 16,6	+ 10,0	- 43,8	- 20,4

\* NHANES I; ^NHANES I epidemiologic follow-up survey

# Il diabete come fattore di prognosi negativa

Hazard Ratio\* di mortalità per CHD in rapporto alla presenza di cardiopatia e/o diabete\*

Patologia	Uomini	Donne
Nessuna	1,0	1,0
Solo CHD°	4,2	1,9
Solo Diabete	2,1	3,8
Diabete+CHD°	6,1	5,4

\*Framingham Study; follow-up 20 a.

°Coronary Heart Disease

# Prevalenza della malattia CV nei pazienti con diabete di tipo 2 in Italia

- Studio DAI: 19.5%
- Studio SFIDA: 20.1%
- Studio MetaScreen: 16.1%


-----

- Prevalenza in Francia: 23.5% (C. Delcourt et al, 1998)
- Prevalenza in Germania: 26.7% (Studio CODE-2, 1999)

-----

- Prevalenza nella popolazione italiana >45 anni: 3.7% (Dati ISTAT, 1998)

# Studio DAI: 201 centri partecipanti





**Nord 43.8%**

**Centro 11.9%**

**Sud - Isole 44.3%**

# Uno studio di incidenza (coorte)



## Lo studio d'incidenza







# Studio DAI: una fotografia dei pazienti seguiti dai servizi italiani


## Fattori di rischio

- Età (mediana) M 65 F67
- Durata (mediana) 8
- Obesi (BMI >30): 38%
- Ipertesi : 82%
- LDL (mediana) 136
- Fumatori: 24,6%
- Microalbuminuria 22%



# Lo Studio DAI (20000 pazienti DM2 italiani): Short-term Risk

distribuzione del rischio: Formule derivate da Framingham





# Il passato dello Studio DAI LE COMPLICANZE CV NEI DIABETICI ITALIANI



DOI: 10.1111/j.1464-5491.2004.01230.x

## The prevalence of coronary heart disease in Type 2 diabetic patients in Italy: the DAI study

The DAI Study Group\*

\*Members of the DAI study group scientific committee: A. Avogaro, C. Giorda, M. Maggini, E. Marmucci, R. Raschetti, E. Sarli, S. Spila-Allegiani, S. Turco, M. Velussi. The list of field investigators is reported in The DAI Study Group (2001) The DAI prospective study on macrovascular complications in patients with Type 2 diabetes. Characteristics of the study population. *Ann Int Super Sanità*, 37: 289-296 (www.iis.it)

Accepted 30 September 2003

### Abstract

**Aims** Type 2 diabetes is associated with at least a twofold increase in risk of coronary heart disease (CHD). We aimed to estimate the prevalence of CHD in the population of Type 2 diabetics cared for by the Italian network of outpatient diabetic units.

**Methods** The DAI (Diabetes and Informatics study group, Italian Association of Diabetologists, and Italian National Institute of Health) study is a multicentre cohort study of patients with Type 2 diabetes. Patients were classified as having CHD if they had: (i) a history for hospital admission for either an acute myocardial infarction (AMI) or angina; (ii) a positive ECG for prior AMI or angina; (iii) a positive history for coronary artery bypass graft; or (iv) a positive history for percutaneous transluminal coronary angioplasty.

**Results** A cohort of 19 468 patients was analysed; 3157 patients had CHD. The majority of events (80%) had occurred after the diagnosis of diabetes and were considered in the CHD prevalence estimate. The prevalence of CHD, adjusted by age and sex, was 9.9%: 11.0% male and 9.0% female. Angina without AMI occurred in 1306 patients; this condition was more frequent in females while a documented AMI was more frequent in males. Therapeutic procedures were performed more frequently in males. A positive association with CHD was found for gender, age at visit, duration of diabetes, hypertension, relatives with CHD, tryglicerides and microvascular complications.

**Conclusions** The prevalence of CHD in this cohort is lower than previously reported; nevertheless, patients attending the diabetic care units may not be fully representative of the general diabetic population in Italy. Revascularization is less frequent in females than in males; microvascular complications and a worse metabolic control are significantly associated with CHD.

*Diabet. Med.* (2004)

**Keywords** coronary heart disease, prevalence, Type 2 diabetes mellitus

### Introduction

Type 2 diabetes is associated with at least a twofold increase in risk of coronary heart disease (CHD) [1]. In the North American population, the age-adjusted prevalence of CHD in diabetic adults is about 45% compared with 25% in subjects


without diabetes [2,3]; a recent survey has confirmed a prevalence of CHD of 51% [4]. However, this figure appears to be significantly lower in Europe; in 1985, the WHO multinational study of vascular disease in diabetes reported a prevalence of CHD of about 30% in males and females [5]. Recent studies from England and France estimated a CHD prevalence of 25 and 18%, respectively [6,7]. In general, past studies report dramatic differences in the prevalence of CHD in diabetic patients. The lower prevalence of large-vessel disease might be associated with a better control of the diabetes, as was partially shown by the UKPDS study [8].

Correspondence to: Prof. Angelo Avogaro, Cattedra di Malattie del Metabolismo, Università degli Studi di Padova, Via Giustiniani 2, 35128, Padova, Italy. E-mail: angelo.avogaro@unipd.it

	Totale
Infarto	6,2
Cardiopatía ischemica	6,1
Tromboembolia cerebrale	2,9
Angioplastica coronarica	0,8
By pass aorto coronarico	2,0
Amputazioni	0,7

# Eventi coronarici all'arruolamento


	Totale		
	Maschi	Femm	Totale
Infarto	9,1	3,3	6,2
Cardiopatìa ischemica	6,0	6,3	6,1
Angioplastica coronarica	1,2	0,5	0,8
By pass aorto coronarico	3,0	1,0	2,0





# L'incidenza di ictus in 4 anni di studio DAI

# Fig1: Incidenza di ictus per incidenti e prevalenti per sesso



# L'incidenza di ictus nei pazienti seguiti dai servizi italiani per 1000 persone/anno

---


*In prevenzione primaria:*

5.5 (95% C.I. 4.2-6.8) nei maschi e 6.3  
(95% C.I. 4.5-8.2) nelle donne

*In prevenzione secondaria (precedenti eventi ats):*


13.7 (95% C.I. 7.5-19.8) nei maschi e  
10.8 (95% C.I. 7.3-14.4) nelle donne

**Fig2b: Incidenza di ictus prevalenti per Hba1c**





# Incidenza di ictus per presenza/assenza di complicanze microvascolari



- no complicazioni microvascolari, uomini
- - - sì complicazioni microvascolari, uomini
- · · · · no complicazioni microvascolari, donne
- · - · - sì complicazioni microvascolari, donne

# Predictors of stroke for 11644 patients without previous CVD (Cox proportional hazards analysis).

Risk factors	Males	P	Females	P
Age at visit (10 years increments)	1.94 (1.46-2.57)	0.00	2.15 (1.66-2.78)	0.00
Duration (3 years increments)	1.03 (0.94-1.12)	0.54		
Waist circumference (5 cm increments)	1.09 (0.99-1.19)	0.09		
HbA1c (20% increments)	1.22 (1.04-1.43)	0.01		
<b>Smoke</b>				
No	1			
Yes	2.29 (1.36-3.87)	0.00		
Former	1.17 (0.70-1.96)	0.55		
<b>Microvascular complications</b>				
No	1		1	
Yes	1.15 (0.74-1.80)	0.53	1.53 (1.01-2.33)	0.05

# Predictors of stroke for 11644 patients without previous CVD (Cox proportional hazards analysis).

## Antihypertensive therapy

No	1	
Yes	1.41 (0.90-2.21)	0.13

## Antihyperglycemic therapy

Diet	1		1	
Oral agents (OA)	1.19 (0.58-2.46)	0.63	2.15 (0.86-5.36)	0.10
Insulin + OA	2.10 (0.80-5.51)	0.13	2.63 (0.91-7.56)	0.07
Insulin	1.61 (0.61-4.21)	0.34	2.28 (0.78-6.66)	0.13

## Geographic area

North	1	
Centre	0.52 (0.22-1.21)	0.13
South	0.62 (0.37-1.01)	0.06

# Predictors of stroke for 2788 patients with previous CVD (Cox proportional hazards analysis).

Risk factor	Adjusted for multiple variables					
	Men			Women		
	HR	(95% CI)	p	HR	(95% CI)	p
Age at visit (10 years increments)	1.86	(1.28-2.70)	0.00	2.54	(1.67-3.88)	0.00
HDL (5mg/dl increments)	0.99	(0.89-1.11)	0.89	0.88	(0.79-0.98)	0.02
<b>Microvascular complication</b>						
No	1			1		
Yes	0.74	(0.41-1.33)	0.32	1.89	(1.04-3.43)	0.04

# Predictors of stroke for 2788 patients with previous CVD (Cox proportional hazards analysis).

## Antihyperglycemic therapy

Diet	1			1		
Oral agents	1.94	(0.59-6.40)	0.28	3.37	(0.46-24.82)	0.23
Insulin + oral agents	5.01	(1.35-18.50)	0.02	4.77	(0.61-37.32)	0.14
Insulin alone	1.79	(0.42-7.71)	0.43	3.95	(0.50-31.14)	0.19

## Previous stroke at enrolment

No	1			1		
Yes	2.83	(1.58-5.07)	0.00	3.12	(1.75-5.57)	0.00

## Total Cholesterol (40mg/dl increments)

0.68	(0.47-0.98)	0.04	1.09	(0.78-1.53)	0.60
------	-------------	------	------	-------------	------

## Lipid-lowering therapy


No	1			1		
Yes	1.07	(0.50-2.29)	0.87	1.80	(0.90-3.61)	0.10

## Cholesterol x lipid-lowering therapy

1.92	(1.09-3.39)	0.02	0.75	(0.44-1.30)	0.31
------	-------------	------	------	-------------	------



# La cardiopatia ischemica in 4 anni di studio DAI




# EVENTI CORONARICI

Tasso di incidenza di primo evento coronario (Inc. per 1000 anni persona) standardizzato **per età**


	Uomini (13.837 anni-persona)			Donne (15.232 anni persona)		
	n	Inc.	IC 95%	n	Inc.	IC 95%
<b>IMA</b>	164	10,3	8,3-12,3	88	4,7	3,3-6,1
<b>Coronarici no IMA</b>	285	18,5	15,8-21,3	344	18,6	15,9-21,4
<b>Tutti gli eventi</b>	<b>449</b>	<b>28,8</b>	<b>25,4-32,2</b>	<b>432</b>	<b>23,3</b>	<b>20,2-26,4</b>
<b>Coronarici maggiori</b>	208	13,1	10,9-15,4	114	5,8	4,3-7,2
<b>Coronarici letali</b>	38	2,6	1,6-3,5	14	0,6	0,3-0,9




Figure 1. Incidence rate of combined (AMI+CHD) events by microvascular complications and sex.




**Incidenze di CHD stimata con Kaplan-Meier per sesso e per complicanze microvascolari negli 11,644 pazienti diabetici di Tipo 2**



# HR [95%CI] Men




# HR [95%CI] Women



# IL FUTURO dello Studio DAI

## Incidenza di recidiva (872 soggetti, 99 eventi)



Soggetti:

872

536

270

142

# CONCLUSIONI

---

1. L'incidenza di ictus e di cardiopatia ischemica nella coorte di diabetici DAI è grosso modo 2 volte quella della popolazione italiana
2. I maschi hanno un'incidenza circa doppia rispetto alle donne
3. Emerge soprattutto nel sesso femminile il ruolo delle complicanze microvascolari (sia nella CHD che nell'ictus)

## CONCLUSIONI 2

---

1. Nell'ictus età e aver già avuto un precedente evento ats, sono importanti fattori di rischio
2. Nel complesso il ruolo della storia precedente del diabete (*HbA1c, complicanze micro, durata, insulina*) sembra avere un ruolo rilevante nello sviluppo di lesioni vascolari


---

Grazie per l'attenzione



# The BLITZ-1 Registry (ANMCO, UTIC ITALIANE)


## Short - Term Survival after AMI



## ***Ricoveri ordinari di pazienti diabetici per complicanze Regione Piemonte anno 2001***

RAGGRUPPAMENTO	%	ETA' MEDIANA	RICOVERI urgenti %	DECESSI %
Vascolari (escluso cuore e cervello)	4,6%	72	43,1%	3,5%
Cerebrovascolari	9,1%	75	72,8%	11,3%
Cardiovascolari	15,4%	70	58,4%	6,8%
Scompenso cardiaco	8,2%	75	75,6%	7,1%
Neurologici puri	0,4%	66	17,4%	0,0%
Renali	2,7%	70	53,5%	4,1%
Oculari	1,9%	73	16,7%	0,0%

# % DI DIABETICI NOTI IN REPARTI DI RICOVERO REGIONE PIEMONTE ANNO 2001



# Effetti della presenza di diabete sulla degenza media ospedaliera per alcune cause di ricovero (Regione Piemonte 2001)

